Cyfuse Biomedical KK

Cyfuse Biomedical KK EBIT per Share

The EBIT per Share of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is -79.05 JPY. In the previous year, EBIT per Share was -110.09 JPY — a change of -28.20% (higher).

EBIT per Share

-79.05JPY

YoY

-28.20%

Last updated:

EBIT per Share of Cyfuse Biomedical KK is 2025 -79.05 JPY. EBIT per Share of Cyfuse Biomedical KK was 2024 -110.09 JPY. It decreases by -28.20% higher compared to the previous year.

The Cyfuse Biomedical KK EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
-36.97 JPY
Jan 1, 2021
7.01 JPY
Jan 1, 2022
-55.02 JPY
Jan 1, 2023
-89.11 JPY
Jan 1, 2024
-110.09 JPY
Jan 1, 2025
-79.05 JPY
Jan 1, 2026 (e)
0.00 JPY
The Cyfuse Biomedical KK EBIT per Share history
YEAREBIT per ShareYoY
est0.00JPY-100.00%
-79.05JPY-28.20%
-110.09JPY+23.54%
-89.11JPY+61.96%
-55.02JPY-884.87%
7.01JPY-118.96%
-36.97JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

EBIT per Share of Cyfuse Biomedical KK is -79.05 JPY in 2025.

EBIT per Share of Cyfuse Biomedical KK changed from -110.09 JPY to -79.05 JPY, representing a -28.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cyfuse Biomedical KK

All Key Metrics — Cyfuse Biomedical KK